Search
Evidence from a recent study, led by MSK urologic surgeon, Behfar Ehdaie, MD, MPH, indicates that more patients with favorable Grade Group 2 prostate cancer can be successfully managed with active surveillance and achieve acceptable oncologic outcomes, even if later treatment is required.
The presence of inflammatory molecules in the cerebrospinal fluid appears to be causing many of the neurologic effects seen in people with COVID-19.
Memorial Sloan Kettering Cancer Center (MSK) and the Robbins Family Foundation are proud to announce today that 13 distinguished MSK nurses and one nursing team were recognized with the 2022 Robbins Family Award for Nursing Excellence. During National Nurses Week (May 6 – 12), MSK recognizes outstanding nurses for exemplary service.
Numerous developments in cellular therapy, multiple myeloma, leukemia and lymphoma are being presented by Memorial Sloan Kettering Cancer Center (MSK) researchers at the American Society of Hematology (ASH) Annual Meeting, which runs December 10-13.
Meet Jaap-Jan “J. J.” Boelens, who joined MSK Kids in 2018 as Chief of the Stem Cell Transplantation and Cell Therapy Service.
MSK announces the establishment of The Tow Center for Developmental Oncology (TCDO).
Physicians and researchers at MSK Kids, Memorial Sloan Kettering Cancer Center’s dedicated pediatric cancer program, achieved several notable advances in 2024, including earning authorization to provide the first gene therapy for sickle cell disease and beta thalassemia, opening a new program for patients with desmoplastic small round cell tumors, translating groundbreaking tumor evolution insights into a new clinical trial strategy for patients with osteosarcoma, and leading cutting-edge research for improving patient outcomes after CAR T cell therapy.
MSK leads the way in optimizing radiation treatment for breast cancer patients.
Researchers at Memorial Sloan Kettering Cancer Center have identified, for the first time, an epigenetic mechanism promoting breast cancer. The team found that inhibition of the PI3K pathway leads to activation of ER-dependent transcription through the epigenetic regulator KMT2D. These findings provide a rationale for epigenetic therapy in patients with PIK3CA-mutant, ER-positive breast cancer. While epigenetic factors have been known to play an important role in various cancers such as leukemia and lymphoma, this is the first evidence found in breast cancer. This research co-led by José Baselga, MD, PhD, Physician-in-Chief and Chief Medical Officer, appears in the March 24, 2017 issue of Science. For more information on this work and to speak with the study authors, contact [email protected].
Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.